Latest Articles

Publication Date
Clinical Value of Circulating Endometrial Cells in the Diagnosis and Stratified Diagnosis of Endometriosis.

Background/Objectives: The diagnosis of endometriosis (EM) remains challenging due to the lack of a perfect diagnostic standard and the poor concordance between clinical symptoms and lesion severity. Although laparoscopy is …

Published: April 15, 2026, midnight
Pathogenesis of Adenomyosis: An Integrated Review of Cellular Origins, Molecular Mechanisms, and Intersecting Diseases.

Adenomyosis is a prevalent disorder of the archimetra, historically conflated with endometriosis but possessing a unique pathobiological trajectory. This review synthesises current molecular evidence to propose a unified mechanistic framework …

Published: April 14, 2026, midnight
BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial - BioSpace

BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial BioSpace

Published: April 13, 2026, 5:57 p.m.
CHCHD2: a bi-organellar fulcrum of mitochondrial homeostasis and reproductive pathology.

Mitochondrial dysfunction has been demonstrated with a role in pathologically driving various obstetric and gynecological (OB/GYN) diseases, but molecular mediators associating mitochondrial dysfunction with discrete pathologies have not been determined …

Published: April 13, 2026, midnight
Unravelling Multilayered RNA Modification Networks in Female Reproduction and Obstetric/Gynaecologic Disorders.

Background/Objective: RNA modifications, including N6-methyladenosine (m6A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), N1-methyladenosine (m1A), pseudouridine (Ψ), N4-acetylcytidine (ac4C), 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) and adenosine-to-inosine (A-to-I) editing, constitute a critical layer of post-transcriptional regulation that …

Published: April 13, 2026, midnight
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times

Published: April 11, 2026, 11:01 a.m.
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers - National Today

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers National Today

Published: April 10, 2026, 4:35 p.m.
Epigenetic Compound Library Screen Identifies Ibrutinib as an Inhibitor of Ovarian Clear Cell Carcinoma Viability.

Ovarian clear cell carcinoma (OCCC) is an endometriosis-associated ovarian cancer subtype. Somatic mutations in OCCC are reported in ARID1A, PIK3CA, and the TERT promoter (TERTp), as well as less commonly …

Published: April 10, 2026, midnight
The AGCES Classification System for Endometriosis: Integrating Adenomyosis with Genital and Extragenital Staging-An Expert Consensus Framework from the American & Global College of Endometriosis Specialists (AGCES).

Background: Current endometriosis classification systems have important limitations in accurately describing total disease burden and predicting clinical outcomes. Existing staging frameworks often fail to integrate adenomyosis and do not adequately …

Published: April 10, 2026, midnight
LINC00632 combines with ERα to target VISTA expression, ameliorating endometriosis progression.

Endometriosis, a prevalent gynecological disease affecting women's health, involves altered immune function. This study investigates the immune checkpoint protein, V-domain immunoglobulin suppressor of T cell activation (VISTA) as a therapeutic …

Published: April 10, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!